DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

@inproceedings{Mross2009DCEMRIAO,
  title={DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study},
  author={Klaus Mross and Ulrike Fasol and Annette Frost and Robin Benkelmann and Jan B. Kuhlmann and Martin Buechert and Clemens Unger and H. E. Blum and J{\"u}rgen Hennig and Tsveta P Milenkova and Jean J L Tessier and Annetta D Krebs and Anderson Joseph Ryan and Richard Fischer},
  booktitle={Journal of angiogenesis research},
  year={2009}
}
BACKGROUND Vandetanib is a once-daily oral inhibitor of VEGFR, EGFR and RET signaling pathways. In patients with advanced colorectal cancer and liver metastases, the effect of vandetanib on tumor vasculature was assessed using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). METHODS Eligible patients received vandetanib 100 or 300 mg/day. DCE-MRI (iAUC(60 )and K(trans)) was used to quantify the primary endpoints of tumor perfusion and vascular permeability. An exploratory… CONTINUE READING